The assay will be designed to predict how pancreatic cancer patients respond to Threshold's investigational drug evofosfamide.
Caris Life Sciences also found that time-to-next treatment could be a surrogate endpoint for survival.
COTA, which also received funding from HealthScape Advisors, said it aims to reduce the amount of money wasted on unnecessary medical treatment.
Syapse is using the Series C funding to hire new staff and extend its Syapse Precision Medicine platform to support disease areas beyond cancer.
Members of Caris' Centers of Excellence for Precision Medicine Network will use the Syapse Precision Medicine Platform to merge data sets.
MedStar Health, which has 10 hospitals in Maryland and Washington DC, is now part of the Caris Centers of Excellence for Precision Medicine Network.
The firms will measure the health and economic impact of the Caris Molecular Intelligence panomic tumor profiling service for cancer patients.
WCC will help develop standards of care and best practices for integrating molecular profiling into cancer care.
The Caris Centers of Excellence for Precision Medicine Network will establish tumor profiling standards and provide access to Caris' database of patient outcomes.
NEW YORK (GenomeWeb) – Caris Life Sciences today announced the launch of a pilot program with the UK's National Health Service to offer patients with ovarian and rare gynecological cancers access to comprehensive tumor profiling.
In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.
The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.
Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.
In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.